Observational studyThe European respiratory journal2025

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.

Olga Halle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.